HTG Molecular Diagnostics, Inc. provided revenue guidance for full year 2022. For the period, total revenue is expected to be approximately $6.4 million, including approximately $2.7 million of HTG Transcriptome Panel (HTP) revenue representing 42% of total revenue.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0025 USD | -.--% | -.--% | +92.31% |
2023 | Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc. | CI |
2023 | Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
+92.31% | 5.54K | |
-25.42% | 16.48B | |
-44.21% | 2.79B | |
+22.46% | 1.94B | |
-12.32% | 1.46B | |
+30.22% | 1.33B | |
-16.15% | 966M | |
+2.58% | 791M | |
-23.37% | 620M | |
+24.06% | 577M |
- Stock Market
- Equities
- HTGMQ Stock
- News HTG Molecular Diagnostics, Inc.
- HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for Full Year 2022